Stopping levothyroxine safely: a UK guide

The question few patients are ever asked

Levothyroxine is the most commonly prescribed medication in the UK. Approximately 3 million people take it, and the vast majority will take it for life — not because the evidence requires this in every case, but because the question of whether it is still needed is almost never asked after it is started. [1]

The indication for levothyroxine encompasses a wide spectrum: frank primary hypothyroidism with clearly elevated TSH and symptoms; subclinical hypothyroidism with mildly elevated TSH and no symptoms; transient hypothyroidism following thyroiditis; over-treatment of borderline TSH; and in some cases, thyroid function that has since normalised. These are clinically very different situations with different long-term treatment implications.

When was the original indication established?

The most important first question in any levothyroxine review is: what was the TSH at the time the prescription was started? A TSH of 2.8 (within normal range) in a patient who was tired and had it checked is a very different starting point from a TSH of 18 (significantly elevated) in a patient with classic hypothyroid symptoms. Both may now be on the same 50 mcg daily prescription. The clinical review that is never done is going back to establish what the original indication actually was.

A significant proportion of levothyroxine prescriptions in primary care were started for subclinical hypothyroidism — TSH mildly elevated, typically between 5 and 10 mU/L, with normal T4 and absent or minimal symptoms. [2] The evidence for treating subclinical hypothyroidism with levothyroxine is weak for most patients, particularly those under 65 — a finding that NICE acknowledges in its thyroid disease guidance. [3]

Transient hypothyroidism: the underrecognised cause

Postpartum thyroiditis affects approximately 5–10% of women and can cause a transient hypothyroid phase, sometimes treated with levothyroxine. In the majority of cases, thyroid function normalises within twelve months of delivery. Many of these women remain on levothyroxine indefinitely without ever having thyroid function rechecked off treatment. [4]

Similarly, thyroiditis following viral illness (subacute thyroiditis) can cause transient hypothyroidism that resolves completely. The appropriate management is treatment during the hypothyroid phase and then reassessment — not indefinite prescribing.

What the British Thyroid Association says

The BTA's 2019 statement on the management of primary hypothyroidism acknowledges that some patients on levothyroxine may not have had a confirmed indication, and that a trial off treatment — under supervision with repeat thyroid function tests — is appropriate in patients where the original indication is uncertain. [5] This is not a niche view; it is official BTA guidance that is infrequently enacted in practice.

How to test whether levothyroxine is still needed

A supervised trial off levothyroxine — with thyroid function checked six to eight weeks after stopping — is the only way to determine whether the original hypothyroidism was permanent or transient, and whether current thyroid function is adequate without medication. This should be done in discussion with a clinician, with a clear plan: stop, check TSH and FT4 at six weeks, and reassess symptoms. If TSH rises significantly and symptoms return, the prescription resumes. If TSH remains normal and the patient feels well, the indication for indefinite prescribing was never confirmed.

This trial is most appropriate for patients with: uncertain original indication; previous transient thyroid event (postpartum thyroiditis, subacute thyroiditis); long gap since diagnosis with no repeat off-treatment testing; or current TSH in the normal range on a dose that has remained unchanged for years, raising the question of whether the dose is appropriate or the condition still active.

Who should not stop levothyroxine

Confirmed primary hypothyroidism — significantly elevated TSH with positive TPO antibodies (Hashimoto's thyroiditis) — is typically lifelong. The autoimmune process does not resolve. Patients with previous thyroid surgery or radioiodine treatment require lifelong replacement. Patients on levothyroxine for thyroid cancer suppression must not alter their dose without oncology input. [3]